Retrophin (RTRX) Lifted to Strong-Buy at ValuEngine

ValuEngine upgraded shares of Retrophin (NASDAQ:RTRX) from a buy rating to a strong-buy rating in a report released on Wednesday.

A number of other research firms have also weighed in on RTRX. BidaskClub raised shares of Retrophin from a hold rating to a buy rating in a research note on Tuesday, August 28th. Zacks Investment Research raised shares of Retrophin from a sell rating to a hold rating in a research note on Thursday, September 27th. Canaccord Genuity started coverage on shares of Retrophin in a research note on Friday, August 17th. They issued a buy rating for the company. Finally, Jefferies Financial Group started coverage on shares of Retrophin in a research note on Tuesday, October 30th. They issued a buy rating and a $44.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. Retrophin has a consensus rating of Buy and an average price target of $43.50.

NASDAQ:RTRX traded down $1.28 during mid-day trading on Wednesday, reaching $25.77. The company’s stock had a trading volume of 208,582 shares, compared to its average volume of 301,596. Retrophin has a 1 year low of $20.09 and a 1 year high of $33.00. The firm has a market cap of $1.12 billion, a PE ratio of -17.18 and a beta of 1.19. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.04 and a quick ratio of 4.99.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.39). Retrophin had a negative return on equity of 35.43% and a negative net margin of 69.38%. The business had revenue of $40.70 million during the quarter, compared to analysts’ expectations of $44.36 million. During the same period last year, the company earned $0.15 earnings per share. The firm’s revenue was up 1.0% compared to the same quarter last year. Sell-side analysts anticipate that Retrophin will post -2.67 EPS for the current fiscal year.

In other Retrophin news, CEO Steve Aselage sold 12,000 shares of the stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $32.00, for a total transaction of $384,000.00. Following the completion of the sale, the chief executive officer now directly owns 257,883 shares of the company’s stock, valued at $8,252,256. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 3.67% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. lifted its position in shares of Retrophin by 10.1% during the first quarter. Principal Financial Group Inc. now owns 21,228 shares of the biopharmaceutical company’s stock valued at $475,000 after buying an additional 1,950 shares during the last quarter. MetLife Investment Advisors LLC lifted its position in shares of Retrophin by 14.9% during the second quarter. MetLife Investment Advisors LLC now owns 18,842 shares of the biopharmaceutical company’s stock valued at $514,000 after buying an additional 2,439 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Retrophin by 11.7% during the second quarter. State Board of Administration of Florida Retirement System now owns 26,595 shares of the biopharmaceutical company’s stock valued at $725,000 after buying an additional 2,790 shares during the last quarter. Meeder Asset Management Inc. lifted its position in shares of Retrophin by 315.6% during the third quarter. Meeder Asset Management Inc. now owns 4,663 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 3,541 shares during the last quarter. Finally, California Public Employees Retirement System lifted its position in shares of Retrophin by 7.3% during the second quarter. California Public Employees Retirement System now owns 56,525 shares of the biopharmaceutical company’s stock valued at $1,541,000 after buying an additional 3,824 shares during the last quarter.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Article: How to Invest in an Index Fund

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply